Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms
- 1 June 2016
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 32 (6) , 612-619
Abstract
Accurate detection and quantification of HIV-1 group O viruses have been challenging for currently available HIV assays. We have developed a novel time-resolved fluorescence (TRF) europium nanoparticle immunoassay for HIV-1 group O detection using a conventional microplate enzyme-linked immunosorbent assay (ELISA) and a microchip platform. We screened several antibodies for optimal reactivity with several HIV-1 group O strains and identified antibodies that can detect all the strains of HIV-1 group O that were available for testing. The antibodies were used to develop a conventional ELISA format assay and an in-house developed europium nanoparticle-based assay for sensitivity. The method was evaluated on both microwell plate and microchip platforms. We identified two specific and sensitive antibodies among the six we screened. The antibodies, C65691 and ANT-152, were able to quantify 15 and detect all 17 group O viruses, respectively, as they were broadly cross-reactive with all HIV-1 group O strains and yielded better signals compared with other antibodies. We have developed a sensitive assay that reflects the actual viral load in group O samples by using an appropriate combination of p24 antibodies that enhance group O detection and a highly sensitive TRF-based europium nanoparticle for detection. The combination of ANT-152 and C65690M in the ratio 3:1 was able to give significantly higher signals in our europium-based assay compared with using any single antibody.Keywords
This publication has 43 references indexed in Scilit:
- Nanoparticle‐Based Immunoassays for Sensitive and Early Detection of HIV‐1 Capsid (p24) AntigenThe Journal of Infectious Diseases, 2010
- Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in CameroonPLOS ONE, 2009
- Census and Analysis of Persistent False-Negative Results in Serological Diagnosis of Human Immunodeficiency Virus Type 1 Group O InfectionsJournal of Clinical Microbiology, 2009
- Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical modelThe Lancet, 2009
- Difficulties in Diagnosing Group O Human Immunodeficiency Virus Type 1 Acute Primary InfectionJournal of Clinical Microbiology, 2008
- Integrase polymorphism and HIV-1 group O diversityAIDS, 2008
- A Seronegative Case of HIV-1 Subtype C Infection in BotswanaClinical Infectious Diseases, 2007
- First Case of Mother-to-Infant HIV Type 1 Group O Transmission and Evolution of C2V3 Sequences in the Infected ChildAIDS Research and Human Retroviruses, 1998
- Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O IsolateVirology, 1997
- Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infectionsThe Lancet, 1994